Document Detail

Propafenone: noninvasive evaluation of efficacy.
MedLine Citation:
PMID:  6496369     Owner:  NLM     Status:  MEDLINE    
Propafenone, a new antiarrhythmic drug, was administered to 60 patients with a history of refractory ventricular tachyarrhythmias, including ventricular fibrillation in 16 and ventricular tachycardia (VT) in 44. A noninvasive protocol was followed utilizing ambulatory monitoring and exercise testing for evaluation of drug effect. The protocol involved acute drug testing with 450 mg of propafenone followed by maintenance therapy with 150 to 300 mg t.i.d. for 4 days. The protocol was completed by 57 patients; in 3 patients side effects developed that necessitated discontinuation of the drug before evaluation. When evaluated by monitoring, 34 patients (60%) responded to the drug, with total elimination of runs of VT, a greater than 90% reduction in couplets and a greater than 50% decrease in the frequency of ventricular premature beats. Based on exercise testing, 36 patients (63%) were deemed responders. When both exercise and monitoring were considered, 30 of 57 patients (53%) responded to propafenone. The acute drug test predicted the response to maintenance therapy in 84% of patients. Propafenone did not change left ventricular function in patients with normal ejection fractions (greater than 50%). However, in those with an ejection fraction less than 50%, propafenone significantly reduced this value (34% vs 29%, p less than 0.01). Side effects occurred in 20 patients (33%) and included nausea, congestive heart failure, aggravation of arrhythmia and conduction abnormalities. Eleven patients have continued on propafenone for an average of 16 months with continued efficacy and freedom from side effects.
P J Podrid; R Cytryn; B Lown
Related Documents :
3673909 - Value of programmed ventricular stimulation in presumed carotid sinus syndrome.
2401059 - Top-resolution frequency analysis of electrocardiogram with adaptive frequency determin...
9144059 - Sodium bicarbonate to correct widened qrs in a case of flecainide overdose.
14516899 - Long-term outcome of patients with recurrent syncope of unknown cause in the absence of...
1376899 - Clinical evaluation of the safety of repetitive intraoperative defibrillation threshold...
793369 - Clinical efficacy of amiodarone as an antiarrhythmic agent.
88989 - Does rectal examination affect serum acid phosphatase levels?
23295279 - A random urine test can identify patients at risk of mesalamine non-adherence: a prospe...
16476719 - Respective role of uraemic toxins and myeloperoxidase in the uraemic state.
Publication Detail:
Type:  Journal Article; Research Support, Non-U.S. Gov't; Research Support, U.S. Gov't, P.H.S.    
Journal Detail:
Title:  The American journal of cardiology     Volume:  54     ISSN:  0002-9149     ISO Abbreviation:  Am. J. Cardiol.     Publication Date:  1984 Nov 
Date Detail:
Created Date:  1984-12-13     Completed Date:  1984-12-13     Revised Date:  2007-11-14    
Medline Journal Info:
Nlm Unique ID:  0207277     Medline TA:  Am J Cardiol     Country:  UNITED STATES    
Other Details:
Languages:  eng     Pagination:  53D-59D     Citation Subset:  AIM; IM    
Export Citation:
APA/MLA Format     Download EndNote     Download BibTex
MeSH Terms
Anti-Arrhythmia Agents / therapeutic use*
Drug Evaluation
Exercise Test
Heart Ventricles
Middle Aged
Propiophenones / therapeutic use*
Stroke Volume / drug effects
Tachycardia / drug therapy*,  physiopathology
Ventricular Fibrillation / drug therapy*,  physiopathology
Grant Support
Reg. No./Substance:
0/Anti-Arrhythmia Agents; 0/Propiophenones; 54063-53-5/Propafenone

From MEDLINE®/PubMed®, a database of the U.S. National Library of Medicine

Previous Document:  Propafenone treatment of recurrent ventricular tachycardia: comparison of continuous electrocardiogr...
Next Document:  Development of the implantable transvenous cardioverter.